Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Carbohydrate load Clear all
Completed Not applicable Interventional

Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins

NCT00593424
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetes Mellitus
Interventions
Low Fat/High Carbohydrate, High Monounsaturated Fat/Low Carbohydrate
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Not applicable Interventional Results available

Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

NCT01157533
View directory record Official record
Conditions
Infection
Interventions
Vancomycin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.

NCT04963413
View directory record Official record
Conditions
Glioblastoma
Interventions
Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00590603
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arsenic Trioxide, Ascorbic Acid and Bortezomib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)

NCT02308228
View directory record Official record
Conditions
Aging
Interventions
Progressive Resistance Training, Metformin
Behavioral · Drug
Lead sponsor
Philip Kern
Other
Eligibility
65 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Results available

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03283696
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Doxorubicin, Ifosfamide, Mesna
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 8, 2026, 2:48 AM EDT
Active, not recruiting Not applicable Interventional

Diet and Health in Adults With Metabolic Syndrome

NCT03935048
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Higher protein, low glycemic load diet
Dietary Supplement
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00066794
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
97
States / cities
Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 8, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Role of Carbohydrate Modification in Weight Management Among Obese Children

NCT00215111
View directory record Official record
Conditions
Childhood Obesity
Interventions
Low carbohydrate, reduced glycemic load, and a control diet
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional

Multi-Media Parent-based Intervention to Promote Dental Hygiene Among Young Children: BeReady2Smile

NCT03637309
View directory record Official record
Conditions
Dental Caries in Children
Interventions
BeReady2Smile Video and App
Behavioral
Lead sponsor
Oregon Research Behavioral Intervention Strategies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

NCT00589563
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
Interventions
anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 8, 2026, 2:48 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes

NCT00228904
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 8, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

NCT06111781
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 2Phase 3 Interventional

Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes

NCT01068197
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
Low Glycemic Load Diet versus Low Fat Diet
Behavioral
Lead sponsor
Nazrat Mirza
Other
Eligibility
7 Years to 14 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes

NCT04416204
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
glycogen loading, No Glycogen Loading
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00228891
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Effect of Pulsatile IV Insulin on diabetic neuropathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 8, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414
View directory record Official record
Conditions
Sarcoma
Interventions
liposomal daunorubicin citrate
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Zero Calorie Drink Products

NCT00525694
View directory record Official record
Conditions
Obesity
Interventions
Glucose tolerance test, glucose tolerance test solution, Diet Coke, Coke Zero
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 8, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction

NCT03764943
View directory record Official record
Conditions
Wound Complication, Wound Heal, Complications Wound, Surgical Wound Infection, Surgical Site Infection, Breast Cancer, Mastectomy; Lymphedema
Interventions
Impact Advanced Recovery
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 8, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers Results available

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

NCT02105766
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
Interventions
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy, Filgrastim
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 8, 2026, 2:48 AM EDT